As compared to TAU, participants in both app conditions evidenced significant decreases in depressive symptoms over time, and these treatment gains were sustained across the trial period. A generalized estimating equation model examining change in depressive symptoms over time by treatment condition indicated a significant interaction between time and treatment condition (χ 2 = 42.21, df = 14, p <. Nearly 70% of Moodivate participants continued to use the app one month after trial enrollment and 50% at the end of the eight-week follow-up period. Moodivate participants on average had 46.76 (SD = 30.10) app sessions throughout the trial duration, spent 3.50 (2.76) minutes using the app per session, and spent 120.76 (101.02) minutes using the app in total throughout the trial. App analytics data were captured to examine Moodivate feasibility (analytics unavailable for control app). Participants completed assessments of depressive symptoms weekly for eight weeks. Participants (N = 52) were recruited from primary care practices between January and December 2017 and were randomized 2:2:1 to receive: 1) Moodivate, 2) an active control Cognitive Behavioral Therapy-based mobile app (“MoodKit”), or 3) Treatment As Usual (TAU no app). The purpose of the present study was to preliminarily examine the feasibility and efficacy of a self-help Brief Behavioral Activation mobile application (app “Moodivate”) for depressive symptoms among adults treated via primary care. Mobile technologies can be leveraged to meet the need for evidence-based psychological depression treatment via primary care.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |